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Abstract
Background Obesity is a chronic complex disease, conse-
quence of an unbalance between energy intake and
expenditure and of the interaction between predisposing
genotype and facilitating environmental factors. The aim of
the study was to evaluate body composition, abdominal fat,
and metabolic changes in a group of severely obese patients
before and after laparoscopic gastric bypass (LGBP) at
standardized (10% and 25%) total weight loss.
Methods Twenty-eight patients (14 M, 14 F; age 41.71±
6.9 years; body mass index (BMI) 49.76±5.8 kg/m2) were
treated with laparoscopic gastric bypass. All evaluations
were performed before surgery and after achieving ~10%
and ~25% weight loss (WL). Body composition was
assessed by bioimpedance analysis; resting metabolic rate
(RMR) was measured by indirect calorimetry.
Results Body weight, BMI, and waist circumference signif-
icantly decreased at 10% and 25% WL. We observed a sig-
nificant reduction of both RMR (2,492±388 at entry vs.
2,098 ± 346.6 at 10%WL vs. 2,035±312 kcal per 24 h at 25%
WL, p=0.001 vs. baseline) as well as of RMR corrected for
fat-free mass (FFM; 35.7±6.7 vs. 34.9±9.0 at 10% WL vs.
33.5±5.4 at 25% WL kilocalorie per kilogram FFM×24 h,
p=0.041 vs. baseline). Body composition analysis showed a
relative increase in FFM and a reduction of fat mass at 25%
WL. A significant reduction in blood glucose, insulin, ho-
meostasis model assessment index was observed. Ultraso-
nography showed a marked decrease in the signs of hepatic
steatosis.
Conclusion In conclusion, our study confirms that LGBP is
a safe procedure in well-selected severely obese patients
and has early favorable effects on both metabolic param-
eters and body composition. Longer-term observations are
required for in-depth evaluation of body composition
changes.
Keywords Severe obesity . Laparoscopic gastric bypass .
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Introduction
Obesity is a chronic complex disease, consequence of an
unbalance between energy intake and expenditure and of
the interaction between predisposing genotype and facil-
itating environmental factors, mainly sedentarism and the
so-called transition diet of affluent societies. The excess
energy is stored as triglycerides into fat cells but also into
other cells as hepatocytes, myocytes, perivascular tissue,
etc.
Adipose tissue, now considered as an endocrine/auto-
crine organ, when enlarged, leads to an increase in
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endoplasmic reticulum and in the number of macrophages
and other stromal cells, which may contribute to the
abnormal secretion of many peptides involved in several
regulatory functions. Furthermore, increased secretion of
free fatty acids from enlarged adipocytes, together with
abnormal peptides secretion, contributes to the development
of many typical complications of obesity: type 2 diabetes,
hypertension, hyperlipidemia, nonalcoholic fatty liver dis-
ease (NAFLD), and some cancers [1, 2]. On the other hand,
complications of obesity are also mechanical, being a direct
consequence of the increased weight of the fat mass (FM)
as in the case of osteoarthritis, hypoventilation syndrome,
some physical disabilities, etc.
Nowadays, the rising prevalence and severity of obesity
may offset the arrays of positive influence on longevity,
typical of developed and affluent societies, and mostly
attributable to lower mortality rates among individuals
above 50 years of age [3]. Indeed, increased abdominal
adiposity associated with a sedentary lifestyle may
significantly affect mortality [4]. Furthermore, sudden
death prevalence, mostly due to cardiovascular events, is
extremely high in severely obese patients, even at a young
age [5].
NAFLD comprises the liver abnormalities associated
with obesity, in the absence of other pathogenetic factors,
and is represented by hepatomegaly, increased liver
enzymes, steatosis with a more complicated pattern up
to nonalcoholic steatohepatitis (NASH), fibrosis, and
cirrhosis [6]. NAFLD usually is reversible after weight
loss; vice versa, NASH has a poorer prognosis and may
worsen to cirrhosis and cancer.
Increased steatosis in obesity is also considered a
clinical consequence of the frequent association with the
metabolic syndrome (MS) and may reflect the increased
free fatty acid flux to the liver associated with hyper-
insulinemia, to increased—albeit insufficient—very-low-
density lipoprotein (VLDL) production, and to increased
secretion of proinflammatory cytokines due to excess
adipose tissue.
The prevalence of liver abnormalities in obesity is quite
high, particularly in severely obese patients as reported in
various studies also carried out in our department [7, 8].
Cholelithiasis is another frequent, often asymptomatic,
finding in obesity especially in obese premenopausal
women [9].
Despite the expected positive effects of weight loss on
NAFLD, there are limited data evaluating body composi-
tion and liver improvements following laparoscopic gastric
bypass (LGBP) in severely obese patients.
The aim of the study was to evaluate body composition,
abdominal fat, and metabolic changes in a group of
severely obese patients before and after LGBP at standard-
ized (10% and 25%) total weight loss.
Patients and Methods
Twenty-eight adult outpatients attending the Obesity Clinic
of the Federico II University Hospital in Naples were
enrolled in the study.
All patients (14 males, 14 females; age 41.71±6.9 years;
body mass index (BMI) 49.76 ± 5.8 kg/m2) underwent
surgery and were treated with laparoscopic gastric bypass.
Patients were recruited, balancing for sex, among those
regularly attending the clinic. Patients underwent all
evaluations before surgery and after achieving ~10% and
~25% weight loss (WL).
At entry, all patients underwent a complete clinical
assessment to evaluate the presence and severity of
associated medical conditions.
Dietary history, food habits, and previous weight loss
efforts were accurately recorded.
To be eligible for the study, patients had to meet the
following criteria: (a) no history of current or past significant
alcohol abuse, i.e., more than 20 g alcohol per day; (b) no
current use of psychotropic drugs or other medications
potentially affecting liver function; (c) serum transaminases
not higher than twice normal value.
Anthropometry
Initial assessment included anthropometric measurements
with standard procedures: height was measured to the
nearest 0.1 cm with a stadiometer and body weight to the
nearest 0.1 kg on a balance beam scale with the subject
barefoot and wearing only light undergarment; height and
weight were recorded and BMI (kg/m2) was calculated;
waist circumference was assessed with a tape measure at
the iliac crests.
Hemato-biochemical Examination
All patients underwent a routine hemato-biochemical
examination including: total and high-density lipoprotein
(HDL) cholesterol, triglyceride (TG), glucose and insulin,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyl transferase (GGT), alkaline phos-
phatase, total bilirubin, hemoglobin, total red blood cell
count, ferritin, transferrin, and fibrinogen. All analytes were
detected using routine laboratory methods.
Metabolic Syndrome Diagnosis
Blood pressure was measured on the right arm, after the
patient had been seated for at least 5 min; a standard
sphygmomanometer, with an adequately sized cuff, was
used. The diagnosis of high blood pressure was made when
values were >130/85 mmHg. Hypercholesterolemia, hyper-
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triglyceridemia, and low-HDL cholesterolemia were diag-
nosed when values were over 200 and 150 mg/dl and below
40 mg/dl in men and <50 mg/dl in women, respectively.
These cutoff points were chosen according to the Adult
Treatment Panel III (ATP III) and the American Heart
Association (AHA) criteria to identify the metabolic
syndrome. The cutoff points for waist circumference were
102 cm in men and 88 cm in women according to ATP III
and 94 cm in men and 82 cm in women according to AHA,
respectively.
The cutoff points for glycemia were ≥110 mg/dl
according to ATP III and ≥100 mg/dl according to AHA,
respectively. The prevalence of metabolic syndrome was
determined considering the combination of three out of five
risk factors as described elsewhere [10].
The homeostasis model assessment (HOMA), based on
serum fasting glucose (mmol/l)×insulin levels (µU/l)/22.5,
was also used as an index of insulin resistance. The MS was
evaluated using both ATP III and AHA criteria.
Fatty Liver Index
The risk of hepatic steatosis was evaluated with the fatty
liver index (FLI), an algorithm based on BMI, waist
circumference, triglycerides, and GGT, as previously
described by other authors [11] and already used by our
group [12].
Single-Frequency Bioimpedance Analysis
Body composition was assessed by bioimpedance analysis
(BIA). Single-frequency BIA was carried out by the same
operator using a BIA 101 device (injection of an alternating
current, at 800 μA and 50 kHz; RJL/Akern System,
Florence, Italy). Measurements were performed on the
nondominant side of the body, at an ambient temperature
of 22–24°C, after voiding and after being in the supine
position for 20 min. A standard tetrapolar technique was
used, placing the measuring electrodes on the anterior
surface of the wrist and ankle and the injecting electrodes
on the dorsal surface of the hand and foot, respectively. The
BIA variables considered were resistance (R), reactance (Xc),
and phase angle (PhA). The bioimpedance index (BI) was
calculated as the ratio height-squared/resistance (cm2 Ω−1).
The instrument was routinely checked with resistors and
capacitors of known values.
Indirect Calorimetry
RMR was measured by indirect calorimetry using a canopy
system (V max 29 N, Sensor Medics, Anaheim, USA) in a
quiet environment and with patients in the supine position
for 30 min before measurement. After allowing patients to
adapt to the instrument for 15–20 min, oxygen consump-
tion and carbon dioxide production were determined for
45 min. Energy expenditure was derived from CO2
production and O2 consumption, with the appropriate Weir
formula, neglecting protein oxidation. The apparatus was
calibrated with gas mixtures of known composition before
each test and regularly checked by burning ethanol.
Ultrasonography
Liver ultrasonography scanning was performed and read by
two independent operators unaware of the patients’ labora-
tory data. An Esaote Mpx Biomedica apparatus equipped
with a convex 3.5-MHz probe and a linear high-frequency
probe (7–13 MHz) was used. Liver steatosis was assessed
semiquantitatively on a scale ranging from 0 to 3 (0: absent;
1: mild; 2: moderate; 3: severe). Steatosis was graded
according to Saverymuttu et al. [13] on the basis of
abnormally intense and high-level echoes from the hepatic
parenchyma, a liver–kidney difference in echo amplitude,
echo penetration into the deep portion of the liver, and
clarity of the liver blood vessel structure [14, 15].
Visceral fat (VF) thickness is the first sonographic index
used for evaluation of visceral adiposity. It was assessed
measuring the distance between the anterior wall of the
aorta and the posterior surface of the rectus abdominis
muscle, with a 3.5-MHz probe [16–18], 1–5 cm above the
umbilicus at the xiphoumbilical line or midway between the
xiphoid process and the umbilicus [19]. The probe was
moved lightly to avoid distortion of tissue due to excess
compression and weight of the probe. The thickness of
subcutaneous fat (SF) was measured at the same level
above the umbilicus, using the high-frequency linear probe
directly on the screen with electronic calipers.
Abdominal Fat Thickness
This value was calculated as the sum of visceral fat
thickness and subcutaneous fat thickness both expressed
in centimeters and measured, as mentioned above, with the
abdominal ultrasound.
Visceral and Subcutaneous Fat Thickness Ratio
This ratio was calculated as visceral fat thickness in
centimeters divided by subcutaneous fat thickness, both
measured, as mentioned above, with the abdominal ultra-
sound. [20]
Patients’ Evaluation and Follow-up
After hospital discharge, all patients were followed weekly
by the doctor and the dietician for evaluation of symptoms
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and careful dietary monitoring and supplementation. One
month after surgery, all patients were invited to change their
lifestyles and were encouraged to start mild physical
activity sessions; in particular, walking up to 30 min a
day was recommended.
Before surgery, all patients underwent psychiatric con-
sultation. This assessment included personal and relational
history, history of psychiatric problems, and current living
state. None of the participants had any evidence of
psychiatric diseases.
All patients were studied at entry and after achieving 10%
and 25% weight loss after laparoscopic Roux-en-Y gastric
bypass.
Operative Technique The laparoscopic procedure began
with the hemi-omentectomy to facilitate the antecolic
transposition of the Roux limb. The height of the
gastroesophageal junction was localized by the transillumi-
nation of the endoscope and the gastric pouch was realized
6 cm caudally and completed toward the angle of His
alongside a 38-F bougie. The gastrojejunostomy was
fashioned manually. The Roux (alimentary) and the
biliopancreatic limb lengths were 150 and 50 cm, respec-
tively. The anastomosis was checked intraoperatively by an
endoscopic hydropneumatic test and, on postoperative day
5, by water-soluble contrast Rx swallow before starting oral
feeding.
Statistical Analysis
The statistical analysis was performed using the SPSS
software (14.0 rel.). Results are expressed as mean±
standard deviation. Comparisons were performed using
unpaired t test and one-way analysis of variance.
The null hypothesis was rejected at a two-tailed p≤0.05.
X2 was used for comparison of categorical data.
Results
Twenty-eight severely obese adult patients (age 41.71±
6.9; range 25–53 years) underwent laparoscopic gastric
bypass. Two of them with cholelithiasis underwent a
cholecystectomy during bariatric procedure. The 10%
WL (true average value being 12.0±2.5%) was achieved
on average after 6 weeks and the 25% WL (true average
value being 24.7±4.2%) about 30 weeks after LGBP. At
entry, five patients had type 2 diabetes treated with diet
and/or hypoglycemic agents; 11 patients took antihyper-
tensive drugs; one patient had hypolipidemic tablets; at
25% WL, all diabetic patients stopped hypoglycemic
agents; only five patients continued antihypertensive
drugs at lower doses; none required lipid-lowering
agents.
Body weight (137.6±23.7 at entry vs. 120.4±20.6 at
10% WL, and vs. 103.9±19.6 kg at 25% WL; p=0.001),
BMI (49.8±5.8 vs. 43.8±5.0 vs. 37.4±4.5 kg/m2; p=
0.001), and waist circumference (141.3±16.1 vs. 132.5±
14.6 vs. 117.9±13.1 cm; p=0.001) significantly decreased
at 10% and 25% WL.
We observed a significant reduction of both RMR, in
absolute values (2,492±388 at entry vs. 2,098±346.6 at 10%
WL vs. 2,035±312 kcal per 24 h at 25% WL, p=0.001 vs.
baseline) as well as of RMR corrected for FFM (35.7±6.7
vs. 34.9±9.0 at 10% WL vs. 33.5±5.4 at 25% WL
kilocalorie per kilogram FFM×24 h, p=0.041 vs. baseline).
Body composition analysis with BIA showed a relative
increase in FFM (52.2±6.2 vs. 51.5±7.4 at 10% WL vs.
64.1±8.9% at 25% WL; p=0.001 vs. baseline) and a
concomitant reduction of FM (47.8±6.2 vs. 48.5±7.4% at
10% WL vs. 34.9±9.0 at 25% WL; p=0.001 vs. baseline) at
25% WL (Table 1). Concerning other BIA parameters: BI
was significantly reduced at 10% WL compared to baseline
(73.1±13.9 vs 65.7±13.1 at 10% p<0.05, vs. 69.3±
16.6 cm2/Ω at 25% WL) whereas PhA changes did not
Table 1 Anthropometric data, body composition, and resting metabolic rate at entry and following 10% and 25% WL in 28 (14 males, 14
females) severely obese patients
Baseline ~10% WL ~25% WL
Mean±SD Mean±SD Mean±SD
Body weight (kg) 137.6±23.7 120.4±20.6* 103.9±19.6**, ***
BMI (kg/m2) 49.8±5.8 43.8±5.0** 37.4±4.5**, ****
Waist circumference (cm) 141.3±16.1 132.5±14.6 117.9±13.1**, ****
FFM (%) 52.2±6.2 51.5±7.4 64.1±8.9**, ****
FM (%) 47.8±6.2 48.5±7.4 35.9±8.9**, ****
RMR (kcal/24 h) 2,492±388 2,098±346.6 2,035±312.9**
RMRc (kcal/kg FFM×24 h) 35.7±6.7 34.9±9.0 33.5±5.4*
RMR resting metabolic rate, RMRc corrected for fat-free mass
*p=0.05 vs. baseline; **p=0.01 vs. baseline; ***p=0.05 vs. 10% WL; ****p=0.01 vs. 10% WL
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reach statistical significance (7.2±0.8 vs. 7.0±1.1 at 10%
WL and 6.6±0.9° at 25% WL, ns).
A significant reduction in blood glucose (104.8±28.2 vs.
87.6±10.9 vs. 78.4±8.0 mg/dl; p=0.001), insulin (24.2±
12.3 vs. 11.1±6.4 vs. 8.5±4.3µg/U; p=0.001), and HOMA
index (from 6.4±3.8 at baseline to 2.4±1.4 at 10% WL,
p=0.001, and to 1.6±0.9 at 25% WL, p=0.001 vs. baseline)
was observed. Serum cholesterol levels decreased in the first
6 weeks (198.0±30.1 vs. 170.9±38.7 mg/dl, p=0.012)
and then remained unchanged at 25% WL (170.9±38.7 vs.
176.4±33.6 mg/dl, p=ns). Triglycerides (166.5±99.3 vs.
131.2±51.4 vs. 101.9±38.6 mg/dl; p=0.002) showed a rapid
and significant reduction, while HDL cholesterol slightly
decreased at 10% WL (46.5±12.7 vs. 41.9±11.1 mg/dl,
p=ns) and significantly increased at 25% WL versus 10%
WL evaluation (41.9±11.1 vs. 51.0±11.1 mg/dl, p=0.017).
Blood pressure values (131.1/85.3±10.5/8.3 vs. 126.9/
82.9±16.9/8.0 at 10% WL vs. 120.7/79.3±13.8/10.0 mmHg
at 25% WL, p=0.017/0.035) and heart rate (79.6±8.3 vs.
74.7±10.7 vs. 71.7±9.6 beats per minute, respectively,
p=0.007) were significantly decreased after surgery com-
pared to baseline.
The prevalence of MS at entry was 60.7% or 67.9% (n=
17/28 or 19/28) according to ATP III or AHA, respectively.
Following treatment, MS prevalence significantly decreased
to 44.4% (n=12/28) at 10% WL and to 17.9% (n=5/28) at
25% WL (p=0.001) considering both criteria.
FLI decreased from baseline to 10% WL (99.3±1.1 vs.
96.1±5.1; p=ns) and to 25% WL (96.1±5.1 vs. 80.4±21.0;
p=0.001).
Some biochemical parameters related to liver function
showed a significant reduction, such as ALT (35.0±15.7 vs.
33.9±18.7 at 10% WL vs. 22.1±16.1 U/ml at 25% WL,
p=0.015), GGT (39.3±32.2 vs. 21.9±12.1 vs. 17.1±12.5 U/
ml, p=0.001), pseudocholinesterase (10,039.8±1,791.6 vs.
7,654.3±1,359.3 vs. 7,845.2±1,870.0 U/l, p=0.001), or a
slight reduction, such as ferritin (176.9±162.0 vs. 116.6±
112.0 vs. 104.7±118.1 ng/ml, p=ns) whereas AST (25.0±
8.2 vs. 28.0±11.9 vs. 22.8±11.8 U/ml, p=ns) remained
unchanged (Table 2). At entry, none of the patients had a
clinically significant increase in transaminases, i.e., not more
than twice of normal values.
Ultrasonography showed a marked decrease in the signs
of hepatic steatosis (one patient missed the echo examina-
tion at 10% WL) as reported in Table 3 and a significant
reduction of total abdominal thickness (12.2±3.0 vs. 6.6±
1.9 cm; p=0.001), as well as of VF and SF in the whole
group (Table 3). This was due to the early and significant
reduction of VF thickness in males (n=14; baseline vs.
10% WL 10.0±2.0 vs. 7.3±2.4 cm; p=0.001 and vs. 25%
WL 10.2±2.1 vs. 4.7±1.2 cm; p=0.001) and to the
subsequent significant reduction of SF thickness in females
(n=14; baseline vs. 10% WL 3.5±0.9 vs. 2.9±1.0 cm;
p=ns and vs. 25% WL 3.5±0.9 vs. 2.2±0.7 cm; p=0.001).
VF/SF significantly decreased from baseline to 10% WL
(3.2±1.5 vs. 2.4±1.0; p=0.026) and to 25% WL (3.2±1.5
vs. 1.6±0.7; p=0.001). When the data were evaluated by
gender, VF/SF significantly decreased in males from baseline
compared to 10% WL (3.9±1.4 vs. 2.8±1.0; p=0.020) and
to 25% WL (3.9±1.4 vs. 1.9±0.7; p=0.001); in females, the
VS/SF was lower at baseline and decreased significantly
only when compared to 25% WL (2.4±1.2 vs. 1.4±0.6;
p=0.011).
Discussion
Based on available evidence, bariatric surgery seems to be
the only consistent, effective, long-term treatment for
morbidly obese patients [21], and the Roux-en-Y gastric
bypass technique has gained the greatest acceptance among
bariatric surgeons in the US [22] and Europe [23].
In the present study, all patients underwent a laparoscopic
gastric bypass. Our patients were studied before undergoing
surgery and once they achieved ~10% and ~25% weight
loss. This is the first time, to our knowledge, that a follow-up
has been performed when a standardized weight loss (10%
and 25% WL) has been achieved.
Biochemistry Baseline ~10% WL ~25% WL
Means±SEM Means±SEM Means±SEM
Glucose (mg/dl) 104.8±28.2 87.6±10.9** 78.4±8.0**
Insulin (μU/ml) 24.2±12.3 11.1±6.4** 8.5±4.3**
HOMA 6.4±3.8 2.4±1.4** 1.6±0.9**
Total cholesterol (mg/dl) 198.0±30.1 170.9±38.7* 176.4±33.6
HDL cholesterol (mg/dl) 46.5±12.7 41.9±11.1 51.0±11.1***
Triglycerides (mg/dl) 166.5±99.3 131.2±51.4 101.9±38.6**
AST (U/ml) 25.0±8.2 28.0±11.9 22.8±11.8
ALT (U/ml) 35.0±15.7 33.9±18.7 22.1±16.1*, ***
GGT (U/ml) 39.3±32.2 21.9±12.1** 17.1±12.5**
Table 2 Hemato-biochemical
data and liver function tests at
entry and following 10% and
25% WL in 28 (14 males, 14
females) severely obese patients
*p=0.05 vs. baseline; **p=0.01
vs. baseline; ***p=0.05 vs.
10% WL
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The degree and duration of overweight, a more central
distribution of body fat, and weight gain over the years
represent well-known risk factors for type 2 diabetes [24].
Weight gain often precedes the onset of diabetes [25]; vice
versa, weight loss, after bariatric surgery, induces a stable
reversion of diabetes [26]. The main metabolic link
between excess body fat and diabetes is hyperinsulinemia
with insulin-resistance known to be the pathogenetic
determinant of the metabolic syndrome. Among other
things, hyperinsulinemia increases hepatic VLDL synthesis
and secretion, PAI-1 synthesis, sympathetic nervous system
activity and renal sodium reabsorption, thus facilitating the
onset of hypertension, hypertriglyceridemia, and liver
steatosis, all typical features of the MS [27].
According to the results of our study, all the MS risk
factors improved with weight loss: our patients showed a
rapid and significant reduction of blood glucose, insulin,
and HOMA, an improvement of dyslipidemia, particularly
hypertriglyceridemia, and a reduction in the prevalence of
the metabolic syndrome. This improvement is probably due
to the drastic restriction of food intake and possible
gastrointestinal hormone adaptation. In fact, the reduction
in HOMA index—due to a drop in insulin serum
concentration and resistance—indicates that the gastric
bypass can modify gastrointestinal endocrine pattern [28].
As recently stated, excess body fat simultaneously
induces a reduced secretion of adiponectin, with tumor
necrosis factor alpha and interleukin 6 hypersecretion
contributing to the insulin resistance; this represents an
endocrine and a metabolic link between adipose tissue and
the metabolic complications associated with excess visceral
body fat and is now encompassed in the definition of the
metabolic syndrome [29].
The frequent association of hypertension with obesity
leads us to consider also in this case a direct active role of
adipose tissue, in particular of splanchnic adipose tissue, in
the development of hypertension.
RMR is known to account for a large percentage of daily
calorie expenditure. Obese individuals generally have
elevated RMR and experience a significant drop in RMR
with weight loss [30, 31]. Carey and colleagues described a
significant RMR reduction only in the first month after
surgery, and these results are in line with lean body mass
(LBM) changes. However, WL may produce a dispropor-
tionate reduction in RMR [32], even when adjusted for
changes in LBM. At 25% WL, we observed a significant
reduction of basal metabolic rate both in absolute values and
when correcting for FFM. In our study, percentage of FFM
appeared unchanged in the initial phase of WL, suggesting a
similar loss of FM and FFM also related to the higher fluid
loss in the short term; vice versa, FFM appeared increased
about 30 weeks after surgery, suggesting a prevalent fat loss
after the acute postoperative period of weight loss. BI has
been demonstrated to be well correlated with total body
water by other authors [33] and in this study it was
significantly reduced in the more precocious phase of weight
loss. PhA is related to intracellular/extracellular body water
ratio and was not significantly changed at 10% and 25%
weight loss, demonstrating a balanced loss of water from the
two compartments as also shown in other groups of patients
[34].
The use of ultrasound for the evaluation of fat
distribution was introduced in the early 1990s [28]. In a
study carried out in obese women, a strong correlation
between visceral fat thickness estimated with sonography
and visceral adipose tissue area measured with computed
tomography (CT) has been observed [35]. Recently, a
review [36, 37] and a research study have confirmed the
accuracy and repeatability of sonographic measurement of
visceral thickness in various patient groups [38–40] and the
correlation of sonographic measurements with CT- and
magnetic-resonance-imaging-based estimates [39, 40]. Al-
so, sonographic measurements have been associated with
metabolic values and central adiposity, more strongly than
anthropometric data [39, 41–43].
Intra-abdominal fat thickness correlates with total cho-
lesterol and fasting glucose levels in men and women at
high risk of cardiovascular disease (CVD) [41], apolipo-
protein B, fasting insulin, and TG levels in obese women
[44] and inversely with HDL cholesterol levels in diabetic
men and women and those at high risk of CVD [41, 44,
45]. Furthermore, intra-abdominal fat thickness has been
Liver ultrasonography Baseline ~10% WL ~25% WL
N (%) N (%) N (%)
No steatosis 1 (3.6) 2 (7.4) 13 (46.4)
Mild steatosis 7 (25.0) 11 (40.7) 9 (32.1)
Moderate and severe steatosis 20 (71.4) 14 (51.9) 6 (21.4)
Total abdominal thickness (cm) 12.2±3.0 9.3±2.8** 6.6±1.9**
Visceral fat (cm) 9.0±3.0 6.4±2.4** 4.4±1.5**, ***
Subcutaneous fat (cm) 3.2±1.1 2.9±0.8* 2.2.±0.8**, ***
VF/SF 3.2±1.5 2.4±1.0* 1.6±0.7**
Table 3 Liver ultrasound at
entry and at 10% and 25% WL
in 28 (14 males, 14 females)
severely obese patients
*p=0.05 vs. baseline; **p=0.01
vs. baseline; ***p=0.01 vs.
10% WL
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correlated with the HOMA index in diabetic patients and
obese women [44, 45]. In a multivariate analysis by Leite et
al. [46], visceral fat thickness was the most significant CVD
marker in both sexes and was a significant independent
predictor of the presence of MS [41].
Our sonographic data showed a marked decrease in
hepatic steatosis and a significant reduction of total
abdominal thickness due to the early and significant
reduction of visceral fat thickness in males and to the
significant reduction of subcutaneous fat thickness in
female. These data were confirmed by the observation of
the reduction in VF/SF; this reduction was significant in
males both from baseline to 10% WL and from baseline to
25% WL, while in females the VF/SF decreased signifi-
cantly only from baseline to 25% WL.
In another study [47] investigating the relationship
between visceral obesity and hepatic steatosis in a small
group of obese women treated with adjustable silicone
gastric banding, the authors found that in the early phase of
rapid weight loss there was also a preferential mobilization
of visceral fat.
In conclusion, in our view, longer-term observations are
required for in-depth evaluation of body fat compartments
and body composition changes following bariatric surgery.
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